On Tuesday, Procept BioRobotics Corp (NASDAQ:PRCT) maintained a Neutral rating from BTIG following the release of their third-quarter financial results for 2024. The company, which has been at the center of debate among investors, reported revenues of approximately $58.4 million. This represents a 66% increase year-over-year and surpasses both BTIG's and consensus estimates of $51.6 million and $53.3 million, respectively.
The company's success this quarter was attributed to the pricing power within its customer base, with around 80% of system placements in the third quarter being HYDROS units. This shift is expected to lead to higher average selling prices (ASPs) for the systems in the future.
Despite US hand piece sales falling slightly below consensus expectations, a 9.2% growth in utilization per system was observed, driven by HYDROS ASPs at approximately $446,000.
In response to the positive results, Procept BioRobotics raised its full-year 2024 guidance to a range of $222.5 million to $223.0 million, up from the previous forecast of $217.0 million. The revised guidance slightly exceeds the third-quarter revenue beat, indicating a robust outlook for the company.
However, there is an expectation of a decline in handpiece utilization in the fourth quarter, which seems to be offset by the higher system ASPs.
Looking ahead to the fourth quarter of 2024, the company is projecting revenues of around $66.5 million, which may have the potential for an upside. Management anticipates a quarter-over-quarter decline in system ASPs, a prediction that BTIG views as unlikely.
Despite the positive developments and the cautious stance going into the earnings release, the current valuation of Procept BioRobotics at approximately 15.5 times next twelve months (NTM) enterprise value to sales (EV/Sales) is seen as offering limited upside for the stock.
In other recent news, PROCEPT BioRobotics has made significant strides in its financial performance and growth strategy. The company initiated a public offering of common stock valued at $175 million, with BofA Securities, Piper Sandler, and Morgan Stanley serving as the joint book-running managers.
Furthermore, PROCEPT also announced a new clinical trial for Aquablation therapy, a promising development in its product offerings.
InvestingPro Insights
Procept BioRobotics Corp's recent financial performance aligns with several key metrics and insights from InvestingPro. The company's impressive 66% year-over-year revenue increase is reflected in InvestingPro Data, which shows a robust revenue growth of 73.74% over the last twelve months as of Q2 2024. This strong growth trajectory is further supported by an InvestingPro Tip indicating a "Significant return over the last week" and "Strong return over the last month," suggesting continued investor confidence in the company's performance.
The article's mention of Procept's raised full-year guidance and potential for upside in Q4 2024 is consistent with the InvestingPro Tip that the stock is "Trading near 52-week high." This optimism is also reflected in the stock's impressive 248.79% price total return over the past year.
However, investors should note that despite the strong revenue growth, an InvestingPro Tip cautions that analysts do not anticipate the company will be profitable this year. This aligns with the reported operating income margin of -62.09% for the last twelve months as of Q2 2024.
For a more comprehensive analysis, InvestingPro offers 14 additional tips for Procept BioRobotics Corp, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.